Associated with longer overall survival after immunotherapy and demonstrating a positive correlation with other predictive biomarkers such as TMB, ZFHX3 mutations can be used as a novel potential predictive marker to direct NSCLC ICI treatment (133). The gene discussed is ZFHX3; the disease is non-small cell lung carcinoma.